Targeting pathways downstream of KRAS in lung adenocarcinoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Oncogenic KRAS mutations are the most frequent genetic alteration in lung cancer.
• Despite understanding KRAS downstream signaling, effective targeted therapies remain elusive.
• Current strategies targeting RAF/MAPK and PI3K/AKT pathways have shown limited clinical success.

Purpose of the Study:

• To review the role of RAF, PI3K, and RAL guanine exchange factor as key KRAS effectors.
• To explore alternative pathways like cytokine activation and autophagy in oncogenic RAS signaling.
• To propose rational combination strategies for multi-targeted therapy against KRAS-driven lung cancer.

Main Methods:

• Literature review and synthesis of evidence on KRAS signaling pathways.
• Analysis of current therapeutic approaches and clinical trial outcomes.
• Identification and discussion of novel therapeutic targets and combination strategies.

Main Results:

• RAF and PI3K are critical downstream effectors of oncogenic KRAS.
• The RAL guanine exchange factor is essential for KRAS-mediated transformation.
• Cytokine signaling and autophagy are co-opted by RAS and represent potential therapeutic targets.

Conclusions:

• Targeting individual KRAS downstream pathways is insufficient for effective lung cancer treatment.
• Alternative pathways like cytokine signaling and autophagy offer new therapeutic opportunities.
• A multi-targeted approach combining inhibitors of various KRAS-regulated pathways is necessary for a potential cure.